{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:09:40Z","timestamp":1774890580639,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"vor","delay-in-days":11400,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1982,1]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> The effect of a saline cathartic combined with activated charcoal or activated charcoal alone on aspirin bioavailability was characterized in six healthy volunteers. Using a random, Latin\u2010square design, subjects were given 975 mg aspirin followed by either water alone, 15 Gm activated charcoal (AC), or 15 Gm activated charcoal plus 20 Gm sodium sulfate (AC + SS) separated by one week. Both AC (44.16 \u00b1 16.85 \u03bcg\/ml) and AC + SS (58.61 \u00b1 10.63 \u03bcg\/ml) decreased (<jats:italic>P<\/jats:italic> &lt; 0.001) the maximal plasma salicylate concentration (<jats:italic>C<\/jats:italic><jats:sub>p<\/jats:sub>max) compared to control (86.61 \u00b1 12.69 \u03bcg\/ml). Urinary salicylate recovery was decreased (<jats:italic>P<\/jats:italic> &lt; 0.01) for AC (57.88 \u00b1 16.26 per cent) and AC + SS (61.00 \u00b1 11.49 per cent) as compared to control (93.73 \u00b1 6.83 per cent), while for area under the plasma concentration\u2010time curve (<jats:italic>AUC<\/jats:italic>) only AC showed a decrease (<jats:italic>P<\/jats:italic> &lt; 0.01) compared to control. Neither AC nor AC + SS differed from each other for <jats:italic>C<\/jats:italic><jats:sub>p<\/jats:sub>max, <jats:italic>AUC<\/jats:italic>, or cumulative urinary recovery. Our findings indicate that the addition of sodium sulfate to activated charcoal has no added effect on limiting aspirin absorption relative to activated charcoal alone.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1982.tb05709.x","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T11:29:05Z","timestamp":1363692545000},"page":"59-64","source":"Crossref","is-referenced-by-count":38,"title":["Saline Catharsis: Effect on Aspirin Bioavailability in Combination with Activated Charcoal"],"prefix":"10.1002","volume":"22","author":[{"given":"INGRID S.","family":"SKETRIS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAMES B.","family":"MOWRY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PETER A.","family":"CZAJKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WILLIAM H.","family":"ANDERSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAVID T.","family":"STAFFORD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1542\/peds.54.3.324","article-title":"Management of acute poisoning with activated charcoal","volume":"54","author":"Corby DG","year":"1974","journal-title":"Pediatrics."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563657508988096"},{"key":"e_1_2_1_4_2","first-page":"71","volume-title":"Cecil Textbook of Medicine","author":"Haggerty RJ","year":"1979"},{"key":"e_1_2_1_5_2","first-page":"949","volume-title":"Harrison's Principles of Internal Medicine","author":"Friedman PA","year":"1980"},{"key":"e_1_2_1_6_2","first-page":"1","volume-title":"Clinical Pharmacy and Therapeutics","author":"Oderda GM","year":"1979"},{"key":"e_1_2_1_7_2","volume-title":"Poisindex.","author":"Rumack BH","year":"1980"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563657708988220"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609985"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600610419"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002807500900701"},{"key":"e_1_2_1_12_2","first-page":"528","article-title":"Treatment of salicylate poisoning","volume":"8","author":"Done AK","year":"1971","journal-title":"Mod Treatment."},{"key":"e_1_2_1_13_2","first-page":"769","article-title":"A simple fluorometric procedure for determining salicylic acid in biological tissues","volume":"54","author":"Chirigos MA","year":"1959","journal-title":"J Lab Clin Med."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563657608995410"},{"key":"e_1_2_1_15_2","volume-title":"A Users Manual for NONLIN and Associated Programs.","author":"Metzler CM","year":"1974"},{"key":"e_1_2_1_16_2","first-page":"1097","article-title":"Comparison of kaolin\u2014pectin and activated charcoal for inhibition of aspirin absorption","volume":"36","author":"Juhl RP","year":"1979","journal-title":"Am J Hosp Pharm."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1969105710"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972133317"},{"key":"e_1_2_1_19_2","first-page":"107","article-title":"Bioavailability monograph\u2014aspirin","volume":"17","author":"Mayersohn M.","year":"1977","journal-title":"J Am Pharm Assoc."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1971.tb46905.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5694\/j.1326-5377.1977.tb99057.x","article-title":"Syrup of ipecacuanha as an emetic in adults","volume":"1","author":"Ilett KF","year":"1977","journal-title":"Med J Aust."},{"key":"e_1_2_1_22_2","unstructured":"CzajkaPA KonradJOSaline cathartics and the adsorptive capacity of activated charcoal for aspirin. Presented at the 15th Annual ASHP Midyear Clinical Meeting San Francisco Cal. December 7-11 1980."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5499.1333"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197601030-00002"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6199.1189"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1982.tb05709.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1982.tb05709.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T05:08:23Z","timestamp":1698815303000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1982.tb05709.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1982,1]]}},"alternative-id":["10.1002\/j.1552-4604.1982.tb05709.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1982.tb05709.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,1]]}}}